文献速递心外重症与机械循环支持

体外内皮细胞培养模型评估心室辅助装置流量调制方法

Evaluation of flow-modulation approaches in ventricular assist devices using an in-vitro endothelial cell culture model.
PubMed 文献 · J Heart Lung Transplant · 2018-11-02

本研究利用人主动脉内皮细胞培养模型(ECCM),验证评估搏动性对Nrf-2抗氧化通路和eNOS/ET-1信号影响,并与患者主动脉壁样本比较。结果显示两种流量调制方案中,异步方案(40次/分,脉压45 mmHg)可能更大程度减少内皮细胞变化,且压力振幅比调制频率对恢复正常抗氧化反应影响更大。

要点

  • ECCM可用于评估CF-VAD流量调制对内皮细胞的影响
  • 异步方案(40次/分,脉压45 mmHg)较同步方案更能减少内皮变化
  • 压力振幅可能比调制频率对恢复正常抗氧化反应更重要

核心结论

  • ECCM培养的HAECs可作为大血管的准确模型,用于识别生物标志物并选择适当流量调制方案。
  • 压力振幅可能比调制频率对恢复正常抗氧化反应影响更大。

研究设计与样本

  • 体外实验研究,使用人主动脉内皮细胞(HAECs)在ECCM中培养,并与患者主动脉壁样本比较。
  • 患者样本包括正常搏动组(n=5)和CF-VAD组(n=5)。
  • 评估两种CF-VAD流量调制方案:同步(80次/分,脉压20 mmHg)和异步(40次/分,脉压45 mmHg)。

主要发现

  • ECCM中HAECs与患者主动脉壁样本均显示Nrf-2激活的抗氧化反应和eNOS/ET-1信号通路在搏动性减弱时差异调节。
  • 异步方案(40次/分,脉压45 mmHg)和同步方案(80次/分,脉压20 mmHg)均可增加Nrf-2调节的抗氧化基因和蛋白表达,并改变eNOS和ET-1水平,异步方案可能更大程度减少变化。

关键数值与推荐

  • 同步方案:80次/分,脉压20 mmHg。
  • 异步方案:40次/分,脉压45 mmHg。
  • 正常搏动患者样本n=5,CF-VAD患者样本n=5。

临床怎么用

  • ECCM模型可用于筛选和优化CF-VAD流量调制方案,以减少搏动性减弱相关不良事件。
  • 选择流量调制方案时,压力振幅可能比调制频率更关键。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous-flow ventricular assist devices (CF-VADs) produce non-physiologic flow with diminished pulsatility, which is a major risk factor for development of adverse events, including gastrointestinal (GI) bleeding and arteriovenous malformations (AVMs). Introduction of artificial pulsatility by modulating CF-VAD flow has been suggested as a potential solution. However, the levels of pulsatility and frequency of CF-VAD modulation necessary to prevent adverse events are currently unknown and need to be evaluated. METHODS: The purpose of this study was to use human aortic endothelial cells (HAECs) cultured within an endothelial cell culture model (ECCM) to: (i) identify and validate biomarkers to determine the effects of pulsatility; and (ii) conclude whether introduction of artificial pulsatility using flow-modulation approaches can mitigate changes in endothelial cells seen with diminished pulsatile flow. Nuclear factor erythroid 2-related factor 2 (Nrf-2)-regulated anti-oxidant genes and proteins and the endothelial nitric oxide synthase/endothelin-1 (eNOS/ET-1) signaling pathway are known to be differentially regulated in response to changes in pulsatility. RESULTS: Comparison of HAECs cultured within the ECCM (normal pulsatile vs CF-VAD) with aortic wall samples from patients (normal pulsatile [n = 5] vs CF-VADs [n = 5]) confirmed that both the Nrf-2-activated anti-oxidant response and eNOS/ET-1 signaling pathways were differentially regulated in response to diminished pulsatility. Evaluation of 2 specific CF-VAD flow-modulation protocols to introduce artificial pulsatility, synchronous (SYN, 80 cycles/min, pulse pressure 20 mm Hg) and asynchronous (ASYN, 40 cycles/min, pulse pressure 45 mm Hg), suggested that both increased expression of Nrf-2-regulated anti-oxidant genes and proteins along with changes in levels of eNOS and ET-1 can potentially be minimized with ASYN and, to a lesser extent, with SYN. CONCLUSIONS: HAECs cultured within the ECCM can be used as an accurate model of large vessels in patients to identify biomarkers and select appropriate flow-modulation protocols. Pressure amplitude may have a greater effect in normalizing anti-oxidant response compared with frequency of modulation.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Haglund TA, Rajasekaran NS, Smood B, et al. Evaluation of flow-modulation approaches in ventricular assist devices using an in-vitro endothelial cell culture model. J Heart Lung Transplant. 2018. PMID: 30503074. doi:10.1016/j.healun.2018.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。